Advertisement

Peroxisome Proliferator-Activated Receptor-α Regulates Fatty Acid Utilization in Primary Human Skeletal Muscle Cells

  1. Deborah M. Muoio12,
  2. James M. Way3,
  3. Charles J. Tanner2,
  4. Deborah A. Winegar3,
  5. Steven A. Kliewer3,
  6. Joseph A. Houmard2,
  7. William E. Kraus1 and
  8. G. Lynis Dohm2
  1. 1Department of Medicine and Cell Biology, Duke University Medical Center, Durham, North Carolina
  2. 2Department of Biochemistry and the Human Performance Laboratory, East Carolina University, Greenville, North Carolina
  3. 3Departments of Molecular Endocrinology and Metabolic Diseases, GlaxoSmithKline, Research Triangle Park, North Carolina

    Abstract

    In humans, skeletal muscle is a major site of peroxisome proliferator–activated receptor-α (PPAR-α) expression, but its function in this tissue is unclear. We investigated the role of hPPAR-α in regulating muscle lipid utilization by studying the effects of a highly selective PPAR-α agonist, GW7647, on [14C]oleate metabolism and gene expression in primary human skeletal muscle cells. Robust induction of PPAR-α protein expression occurred during muscle cell differentiation and corresponded with differentiation-dependent increases in oleate oxidation. In mature myotubes, 48-h treatment with 10–1,000 nmol/l GW7647 increased oleate oxidation dose-dependently, up to threefold. Additionally, GW7647 decreased oleate esterification into myotube triacylglycerol (TAG), up to 45%. This effect was not abolished by etomoxir, a potent inhibitor of β-oxidation, indicating that PPAR-α–mediated TAG depletion does not depend on reciprocal changes in fatty acid catabolism. Consistent with its metabolic actions, GW7647 induced mRNA expression of mitochondrial enzymes that promote fatty acid catabolism; carnitine palmityltransferase 1 and malonyl-CoA decarboxylase increased ∼2-fold, whereas pyruvate dehydrogenase kinase 4 increased 45-fold. Expression of several genes that regulate glycerolipid synthesis was not changed by GW7647 treatment, implicating involvement of other targets to explain the TAG-depleting effect of the compound. These results demonstrate a role for hPPAR-α in regulating muscle lipid homeostasis.

    Footnotes

    • Address correspondence and reprint requests to Deborah M. Muoio, P.O. Box 3327, Duke University Medical Center, Durham, NC 27710. E-mail: muoio{at}duke.edu.

      Received for publication 22 August 2001 and accepted in revised form 4 January 2002.

      D.M.M. has received funding from GlaxoSmithKline to support studies focused on developing new drug therapies to treat muscle insulin resistance.

      ACO, acyl-CoA oxidase; ASM, acid-soluble metabolite; CPT1, carnitine palmityltransferase 1; DFM, differentiation media; DGAT, diacylglycerol acyltransferase; DMEM, Dulbecco’s modified Eagles medium; FBS, fetal bovine serum; GM, growth media; GPAT, glycerol-3-phosphate acyltransferase; HSKMC, human skeletal muscle cell; MCAD, medium-chain acyl-CoA dehydrogenase; MCD, malonyl-CoA decarboxylase; PDH, pyruvate dehydrogenase; PDHK, PDH kinase; PPAR, peroxisome proliferator–activated receptor; RTQ-PCR, real-time quantitative PCR; SREBP1, sterol regulatory element binding protein 1; TAG, triacylglycerol; TCA, tricarboxylic acid.

    | Table of Contents
    Advertisement